An observational study in Relapsed Hepatoblastoma and Refractory Hepatoblastoma, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Children's Hospital Medical Center, Cincinnati · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Hepatoblastoma with a site in United States — 11 open to participants now, 25 under way, 1 of them phase 3. Hepatoblastoma · United States.
Among the 54 studies in Hepatoblastoma with a site in United States, this one is one of 4 that started in 2022, is one of 5 observational ones, reaches primary completion later than 22 of the 24 other live ones, and was the 50th registered.
82 studies on the registry are indexed under Hepatoblastoma; 17 are open to participants now.
Browse Hepatoblastoma studies →11 of the 54 studies in Hepatoblastoma with a site in United States are open now. Recruiting first, the newest first:
Seattle Children's Hospital · Sites in United States
Ages 1–26
Baylor College of Medicine · Sites in United States
Ages up to 21
Eureka Therapeutics Inc. · Sites in United States
Ages 1–21
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Children's Oncology Group · Sites in United States
Ages 12 mo–30 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Hepatoblastoma studies recruiting now, 2 (13%) set no upper age limit and 13 (81%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 26 · Phase 3 5
First in 1992; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 125 across 16 observational studies indexed under Hepatoblastoma.
Median enrollment 23 across the 48 interventional studies, 359 across the 5 observational. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 54 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 2 studies filed under Hepatoblastoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Hepatoblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03533582Phase 3Children's Oncology GroupCisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | 2027-03-31 |
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT04308330New York Medical CollegeVorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | 2026-12-31 |
| NCT01804634Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsReduced Intensity Haploidentical BMT for High Risk Solid Tumors | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Hepatoblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are limited data regarding the biology and treatment of relapsed/refractory hepatoblastoma (rrHBL). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of rrHBL. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with rrHBL, prospectively. Cases are identified through:
The following data/materials will be collected:
Clinical Data: Demographic data, date of diagnosis, pathology, radiological imaging data, signs and symptoms at diagnosis, molecular and biological data, staging details including sites of disease, detailed treatment data (e.g. types and dates of surgeries/interventional therapy (if any), medical/systemic therapy, radiotherapy), response to treatment (imaging and tumor markers), dates of progression, types of progression (local or metastatic), and follow-up data. The demographic and clinical data collected are abstracted and entered into an electronic data system secured by password protection. Collection of existing molecular and/or genomic data or analysis that has been performed will also be included.
Research Specimens:
Tissue (fresh/frozen/FFPE) from diagnosis and all subsequent timepoints where tissue was acquired (for example at each relapse and/or progression) will be requested for all enrolled patients and sent for central review to the study pathologist and stored in the rrHBL biorepository within the Cancer and Blood Disease Institute at Cincinnati Children's Hospital Medical Center. Future research testing may be conducted on this tissue.
Optional research specimens:
Pending consent specification of family/patient, and resources, specimens may be sent directly to collaborating laboratories to proceed with tumor modeling and drug testing, or other translational research with PI or designee via an Institutional Review Board approved project.
Registry clinical data will be correlated with biological/bioinformatic and genomic data. Data stored in the Registry may be used to provide statistical data for scientific presentations and for preparation of peer- reviewed manuscripts.
Patients with relapsed or refractory Hepatoblastoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with relapsed/ refractory Hepatoblastoma
Other: Biospecimen collection
Clinical information and biospecimens will be collected
Characterization of relapsed or refractory Hepatoblastoma
To characterize rrHBL across all age groups with regards to demographics, presenting features, pathology, radiology, clinical course, treatments and response
Time frame: From enrollment until data analysis is complete - assessed up to 40 years
Create biorepository of specimens
To create a biorepository of specimens from patients with rrHBL or suspected to have rrHBL to enhance molecular/biological investigations
Time frame: From enrollment until data analysis is complete - retained up to 40 years
Clinical data and biological data correlation
To correlate registry clinical data with biological/bioinformatic data
Time frame: From enrollment until data analysis is complete - assessed up to 40 years
Plan to share: Undecided — Studies submitted from other researchers will be approved by the Hepatic Tumors Research Consortium Steering Committee (HTRC SC) and will have appropriate Institutional Review Board approvals/determinations received by the Registry staff.
Started Sep 2022 (actual). Primary completion is estimated for Sep 2032, 119 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →